Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADX106772
- Development stage
- Discontinued
- Lead developer
- Addex Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
ADX106772 is an experimental small molecule positive allosteric modulator (PAM) of the metabotropic glutamate receptor 2 (mGlu2). Developed by Addex Therapeutics, the compound is designed to reduce excessive glutamate release in brain regions associated with addiction. Preclinical studies conducted in collaboration with The Scripps Research Institute have demonstrated that ADX106772 selectively attenuates oxycodone self-administration and cue-induced reinstatement of drug-seeking behavior in animal models of opioid use disorder (OUD), without disrupting natural reward pathways. It is currently classified as a historical research or tool compound.
02
Targets
GRM2 (mGluR2)
Beyond the preview
Go deeper on ADX106772.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADX106772.